El-Khazragy, NGhozy, SEmad, PMourad, MRazza, DFarouk, YKMohamed, NAAhmed, MKYoussef, TBahnasawy, YMElmasery, S2020-11-192020-11-192020-111750-743Xhttps://doi.org/10.2217/imt-2020-0181https://qrgo.page.link/EdA67Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory hematological malignancies. Despite the great results of the CAR-T-cell therapy, many tumors are still able to avoid immune detection and further elimination, as well as the possible associated adverse events. Herein, we highlighted the recent advances in CAR-T-cell therapy, discussing their applications beneficial functions and side effects in hematological malignancies, illustrating the underlying challenges and opportunities. Furthermore, we provide an overview to overcome different obstacles using potential manufacture and treatment strategiesen-USadoptive cell therapychimeric antigen receptors (CAR-T)hematological malignanciesimmunotherapyleukemiaArticlehttps://doi.org/10.2217/imt-2020-0181